Drug General Information
Drug ID
D0Q3ES
Former ID
DCL000051
Drug Name
APD668
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Discontinued in Phase 1 [548256]
Company
Arena Pharma.
Structure
Download
2D MOL

3D MOL

Formula
C19H23N5O3S
Canonical SMILES
C1CN(CCN1CCCCN2C(=O)C3=CC=CC=C3S2(=O)=O)C4=NC=CC=N4
InChI
1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2
InChIKey
TZJUVVIWVWFLCD-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Glucose-dependent insulinotropic receptor Target Info Agonist [551535]
KEGG Pathway cAMP signaling pathway
Insulin secretion
WikiPathways Incretin Synthesis, Secretion, and Inactivation
References
Ref 548256Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023882)
Ref 551535Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.